Medicilon pushes on preclinical development of drugs

On August 2, 2019, “The Medicilon 15th Anniversary Series Tour Forum – Preclinical Research Seminar” was held at the Pudong International Talent Hub.  There were 150 pharmaceutical R&D experts from nearly 100 pharmaceutical companies to attend the seminar.  The seminar was hosted by Shanghai Medicilon Inc. and co-organized by Pudong International Talent Hub and Shanghai Pudong Bio Industry Association.

The opening speech of the seminar was given by Ms. Guifeng Ying, the Project Leader of Pudong International Talent Hub.  Hereafter, Dr. Chunlin Chen, CEO of Medicilon, kicked off the report on the dual application of the new drug application (IND) for both CFDA and US FDA.  During the speech, Dr. Chen emphasized on the pharmacology, pharmacokinetics, pharmacodynamics and toxicological parameters of the drug preparation, the dual application, CFDA and US FDA, requirement of IND and the innovative drug R&D platform of Medicilon.

Dr. Shuangqing Peng, VP and Head of the Preclinical Research Department, and Dr. Xiaodong Zhang, VP of Preclinical Toxicology, gave the speech on several topics such as innovative drug non-clinical safety evaluation strategies, non-clinical safety evaluation test completion time requirements, and non-clinical safety evaluation experimental design.

The final session of the seminar was “Topic Sharing”.  Dr. Zhen Zhang from Shanghai Synergy Pharmaceutical Sciences Co., Ltd and Dr. Ya Geng from Shanghai Jiyu Pharmaceutical Technology Co., Ltd. shared their experience on drug applications.

This seminar set up an effective platform for the research progress and prospects of preclinical drugs.  The seminar promoted networking between experts, professors, scholars, and participants.  Medicilon is looking forward to the next seminar!

Related Articles:

Preclinical and clinical stages of drug development

Medicilon hosted a Preclinical Development of Innovative Drugs Summit